MOVING AHEAD REQUIRES A SURE PATH FORWARD
Trials are inherently risky, and every detail matters. We spot risks before they become problems to help you avoid costly delays through an array of solutions that provide confidence at every turn.
ENHANCE TRIAL OVERSIGHT
Run more efficient trials by unlocking hidden insights
enable site optimization
Generate high-quality data by optimizing site selection and performance
increase patient engagement
Equip patients with the tools to take control of their health
ensure safety and measure efficacy
By driving high-quality data
THE ERT EXPERT PLATFORM
The ERT EXPERT® platform is the underlying proprietary technology that powers all ERT solutions. Improve trial visibility and performance and reduce time-to-market with confidence, agility and acceleration.
MINIMIZe RISK AND UNCERTAINTY
We enable the flexibility and adaptability you need to accelerate through hurdles for faster speed to market. Here’s how:
Every trial runs into unexpected challenges. With more than 13,000 trials under our belt, we’ve seen most of them before and have the expertise to put your trial back on course.
We’ll protect the success of your trial before there’s ever an issue, with near real-time access to study, program and enterprise-level performance.
NEWS & EVENTS
May 8, 2018
Lung Safety and Disease Progression in Non-Respiratory Trials
Register for our webinar to discover how to exploit objective, reliable pulmonary function data as relevant outcome parameters in non-respiratory trials, ultimately delivering value in therapeutic research and drug development.
April 18, 2018
ERT Receives Sixth Consecutive Award for Outstanding Customer Service
Remains committed to exceeding expectations, driving high satisfaction.
April 4, 2018
Patient Centered Apps
This article – featuring comments by ERT’s Tim Davis – outlines how the pharmaceutical industry is overcoming long-standing challenges to develop more patient centered apps that enable all patients to manage their conditions and achieve better health outcomes.